表格類別： 股票 狀態： 新提交 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 公司名稱： 長風藥業股份有限公司 呈交日期： 2026年1月2日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02652 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份 ...

Group 1 - The company, Changfeng Pharmaceutical (02652.HK), announced a share buyback on December 31, 2025, costing HKD 1.4565 million to repurchase 43,000 shares [1] - The buyback price ranged from HKD 33.34 to HKD 36 per share [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 長風藥業股份有限公司 呈交日期： 2025年12月31日 (i) 上市發行人已收取其在是次股份發行或庫存股份出售或轉讓應得的全部款項； (viii) 有關債券、借貸股份、票據或公司債券的信託契約/平邊契據經已製備及簽署，有關詳情已送呈公司註冊處處長存檔（如法律如此規定）。 第一章節註釋： 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02652 | 說明 | | | | | | A. 已發 ...

Group 1 - The company, Changfeng Pharmaceutical (02652), announced a share buyback plan, intending to repurchase 24,000 shares at a cost of HKD 830,200 [1]

智通财经APP讯，长风药业(02652)发布公告，于2025年12月30日斥资83.02万港元回购2.4万股。 ...

格隆汇12月30日丨长风药业(02652.HK)公告，12月30日耗资83万港元回购2.4万股。 ...

呈交日期： 2025年12月30日 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 長風藥業股份有限公司 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02652 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事 ...

Core Viewpoint - Changfeng Pharmaceutical (02652) has announced that its new inhaled nucleic acid drug development project has been selected as a key project under Jiangsu Province's 2025 major science and technology initiative "Innovative Biopharmaceuticals" [1] Group 1: Project Overview - The project focuses on addressing key challenges in the pulmonary delivery of small nucleic acid (siRNA) drugs and aims to advance the translational research and preclinical development of inhaled nucleic acid candidates [1] - The project plans to support the development of inhaled nucleic acid candidates targeting major respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and pulmonary fibrosis [1] Group 2: Strategic Importance - The selection of this project is considered strategically significant for the company, further validating the strength of its technological platform [1] - Delivery technology is identified as a critical barrier for siRNA treatments in the lungs, and the company has developed an efficient lung-targeted delivery system that has shown promising therapeutic potential in preclinical studies [1] Group 3: Future Commitment - The recognition from relevant departments and expert reviewers reflects the company's and its partners' capabilities in cutting-edge delivery technology research and development [1] - The company is committed to continuous technological innovation to provide more valuable treatment options for patients and to create sustainable long-term returns for shareholders [1]

Core Viewpoint - The project led by the company for the development of a novel inhaled nucleic acid drug has been selected as a major technological project in Jiangsu Province for 2025, focusing on innovative biopharmaceuticals [1] Group 1: Project Overview - The project addresses key challenges in the pulmonary delivery of small nucleic acid (siRNA) drugs and aims to advance the translational research and preclinical development of inhaled nucleic acid candidates [1] - The project plans to support the research and development of inhaled nucleic acid candidates targeting major respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and pulmonary fibrosis [1] Group 2: Strategic Importance - The selection of this project is considered strategically significant for the company, further validating the strength of its technological platform [1] - Delivery technology is identified as a critical barrier for siRNA treatments in the lungs, and the company has developed an efficient lung-targeted delivery system [1] Group 3: Research and Development - The project encompasses the optimization of delivery systems, formulation and process development, preclinical research, and preparation for new drug clinical trial applications [1] - The candidates developed under this project have shown promising therapeutic potential in preclinical studies [1] - The recognition from relevant departments and expert reviewers highlights the company's collaborative research capabilities in advanced delivery technology [1]

Core Viewpoint - The announcement highlights that Changfeng Pharmaceutical's new inhaled nucleic acid drug development project has been selected as a key project under Jiangsu Province's 2025 major science and technology initiative for "Innovative Biopharmaceuticals" [1] Group 1: Project Overview - The project focuses on addressing key challenges in the pulmonary delivery of small nucleic acid (siRNA) drugs, aiming to advance the translational research and preclinical development of inhaled nucleic acid candidates [1] - It plans to support the research and development of inhaled nucleic acid candidates targeting major respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and pulmonary fibrosis [1] Group 2: Strategic Importance - The selection of this project is deemed strategically significant for the company, further validating the strength of its technological platform [1] - Delivery technology is identified as a critical barrier for siRNA treatments in the lungs, and the company has developed an efficient lung-targeted delivery system that has shown promising therapeutic potential in preclinical studies [1] Group 3: Future Commitment - The project reflects recognition from relevant departments and expert reviewers of the company's collaborative research capabilities in cutting-edge delivery technology [1] - The company is committed to continuous technological innovation to provide more valuable treatment options for patients and to create sustainable long-term returns for shareholders [1]